Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down – What’s Next?

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) gapped down before the market opened on Thursday . The stock had previously closed at $9.92, but opened at $9.33. Telix Pharmaceuticals shares last traded at $9.29, with a volume of 59,117 shares traded.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on TLX shares. Wedbush reissued an “outperform” rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a report on Thursday, August 28th. Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Wednesday, October 8th. Citigroup began coverage on Telix Pharmaceuticals in a report on Thursday, September 18th. They issued a “buy” rating and a $22.00 price objective for the company. UBS Group lowered their target price on Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, September 23rd. Finally, HC Wainwright reduced their price objective on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $21.00.

Telix Pharmaceuticals Trading Down 3.6%

The firm’s fifty day moving average is $9.98 and its 200 day moving average is $12.21.

Hedge Funds Weigh In On Telix Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TLX. Millennium Management LLC bought a new position in shares of Telix Pharmaceuticals during the 3rd quarter worth about $1,883,000. Pier Capital LLC bought a new stake in shares of Telix Pharmaceuticals during the second quarter worth $3,037,000. Portland Investment Counsel Inc. bought a new position in shares of Telix Pharmaceuticals in the third quarter worth about $1,225,000. Lazard Asset Management LLC bought a new position in Telix Pharmaceuticals in the 3rd quarter valued at $1,097,000. Finally, Russell Investments Group Ltd. bought a new stake in Telix Pharmaceuticals during the 2nd quarter worth about $975,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.